Studies

58 studies · Download as JSON

• Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Benefit
• A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin TherapyMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head StudiesMeta-analysis · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric SurgeryRetrospective cohort · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With ObesityRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysisRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEFAnimal study · 2026 · Study tier 4 · Not human evidence · Unclear · Unreviewed automatic assessment
• Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched studyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Benefit · Unreviewed automatic assessment
• Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Null · Unreviewed automatic assessment
• Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese miceAnimal study · 2026 · Preliminary · Not human evidence · Unclear · Not peer reviewed · Unreviewed automatic assessment
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity EraMeta-analysis · 2026 · Preliminary · Different population · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication OpportunitiesRetrospective cohort · 2026 · Preliminary · Different population · Null · Not peer reviewed · Unreviewed automatic assessment
• Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsRetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USARetrospective cohort · 2026 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Unclear · Unreviewed automatic assessment
• Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSARandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• FDA prescribing information: Zepbound, ZEPBOUND (TIRZEPATIDE) - label effective 2026-08-28Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic ReviewSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response EvidenceSystematic review · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life OutcomesSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity ReactionsPharmacovigilance · 2026 · Study tier 4 · Population unclear · Null · Unreviewed automatic assessment
• Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled TrialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Unreviewed automatic assessment
• FDA prescribing information: MOUNJARO (TIRZEPATIDE) - label effective 2026-07-29Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
• Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
• Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT TrialRandomized trial · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic ControlSystematic review · 2026 · Study tier 2 · Different population · Mixed · Unreviewed automatic assessment
• Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic BenefitsMeta-analysis · 2026 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction · Unreviewed automatic assessment
• Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance databasePharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
• Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Harm direction · Unreviewed automatic assessment
• Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Population unclear · Null · Unreviewed automatic assessment
• Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort studyRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
• Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT TrialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Unreviewed automatic assessment
• Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2025 · Study tier 2 · Different population · Unclear · Unreviewed automatic assessment
• The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysisRetrospective cohort · 2025 · Study tier 3 · Partial match · Benefit
• Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trialRandomized trial · 2025 · Study tier 3 · Different population · Benefit · Unreviewed automatic assessment
• Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
• Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
• Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis · 2025 · Study tier 2 · Population unclear · Mixed · Unreviewed automatic assessment
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityTwo phase 3, double-blind, randomized, controlled trials under one master protocol; parallel-arm, placebo-controlled, 52-week treatment duration; trial 1 (gpi1, not on pap) and trial 2 (gpi2, on pap). · 2024 · Study tier 2 · Different population · Benefit
• Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategiesNarrative review · 2024 · Not rated · Population unclear · Mixed
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical TrialRandomized trial · 2024 · Study tier 1 · Different population · Benefit · Industry funded
• The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysisClinical trial · 2022 · Study tier 4 · Different population · Null · Unreviewed automatic assessment